Kidney transplantation for primary focal segmental glomerulosclerosis: Outcomes and response to therapy for recurrence

Transplantation

Volumn 87, Issue 8, 2009, Pages 1232-1239

  Hickson, Latonya J ^a   Gera, Manish ^a   Amer, Hatem ^a   Iqbal, Corey W ^a   Moore, Therese B ^a   Milliner, Dawn S ^a   Cosio, Fernando G ^a   Larson, Timothy S ^a   Stegall, Mark D ^a   Ishitani, Michael B ^a   Gloor, James M ^a   Griffin, Matthew D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Focal segmental glomerulosclerosis; Kidney transplantation; Plasmapheresis; Recurrent disease; Rituximab

Indexed keywords

RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GRAFT SURVIVAL; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65549091459     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819f12be     Document Type: Article

References (29)

1. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004; 44: 815.
2. Artero M, Biava C, Amend W, et al. Recurrent focal glomerulosclerosis: Natural history and response to therapy. Am J Med 1992; 92: 375.
3. Andresdottir MB, Ajubi N, Croockewit S, et al. Recurrent focal glomerulosclerosis: Natural course and treatment with plasma exchange. Nephrol Dial Transplant 1999; 14: 2650.
4. Pardon A, Audard V, Caillard S, et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant 2006; 21: 1053.
5. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5: 1179.
6. Baum MA. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 2004; 8: 329.
7. Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59: 328.
8. Abbott KC, Sawyers ES, Oliver JD III, et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37: 366.
9. Cibrik DM, Kaplan B, Campbell DA, et al. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant 2003; 3: 64.
10. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878.
11. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22: 106.
12. Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7.
13. Artero ML, Sharma R, Savin VJ, et al. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23: 574.
14. Pradhan M, Petro J, Palmer J, et al. Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 2003; 18: 934.
15. Deegens JK, Andresdottir MB, Croockewit S, et al. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004; 17: 151.
16. Iguchi Y, Tanabe K, Yagisawa T, et al. Plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis of kidney allograft in adult recipients. Ther Apher 1997; 1: 191.
17. Otsubo S, Tanabe K, Shinmura H, et al. Effect of post-transplant double filtration plasmapheresis on recurrent focal and segmental glomerulosclerosis in renal transplant recipients. Ther Apher Dial 2004; 8: 299.
18. Ohta T, Kawaguchi H, Hattori M, et al. Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 2001; 71: 628.
19. Ohta T, Sakano T. Post-transplant recurrence of focal segmental glomerulosclerosis. Kidney Int 2001; 59: 2374.
20. Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5: 2907.
21. Nozu K, Iijima K, Fujisawa M, et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005; 20: 1660.
22. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354: 1961.
23. Marks SD, McGraw M. Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 2007; 22: 158.
24. Gossmann J, Scheuermann EH, Porubsky S, et al. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 2007; 20: 558.
25. Hristea D, Hadaya K, Marangon N, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007; 20: 102.
26. Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67: 250.
27. Yabu JM, Ho B, Scandling JD, et al. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008; 8: 222.
28. Meyer TN, Thaiss F, Stahl AK. Immunoadsorption and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007; 20: 1066.
29. Howard RJ. The challenging triangle: Balancing outcomes, transplant numbers and costs. Am J Transplant 2007; 7: 2443.